SGP Liposomal series products were certificated by FSSC22000, ISO22000, HACCP.
The prescriptions, specifications and stability studies of Liposomal series products were confirmed.
Scaled-up the production of Liposomal Food Additive.
Construction of cGMP workshops for Liposomal Food Additives.
Started new business of oral liposome as food additive.
Stared R&D of Liposomal Food Additive, such as Liposomal NMN, Liposomal Co-Q10, Liposomal Glutathione, etc.
GF07 was submitted Pre-IND as a new drug.
Compound 20(S)-Ginsenoside Rg3 Paclitaxel Liposome for Injection (GF07) was scaled-up in production, CMC and PK/PD studies started.
Xiamen Ginposome Pharmaceutical Co., Ltd. was established.
The Liposomal DDS technology based on Ginsenosides as membrane material was developed.
Ginposome-Rg5/Paclitaxel and Rg3/Paclitaxel were developed.
SGP, the company, was established, whileas the word Gin-posome comes from the two words Ginsenoside+Liposome.
Micellar-Rg5/Paclitaxel was failed in Vivo.
The discovery was found by Dr. Kyu Nung Chung of Ginsenosides (Rg3/Rg5/Rk1=1:2:1) can self-form micelles, and make Paclitaxel into water-soluble.
The Micellar DDS based on Ginsenosides as membrane material was developed.
Started the R&D of Compound Ginsenosides and Paclitaxel to solve the Multi-Drug Resistance (MDR) problems.
If you have any requirements, please contact us freely and we will provide you the best solution.
